Author Archives: webmaster

Lower risk of heart failure, cardiovascular disease and overall mortality in patients with type 2 diabetes following initiation of SGLT2 inhibitors

The article Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis, recently published in Lancet Diabetes & Endocrinology,  shows that the use of sodium-glucose co-transporter-2 (SGLT2) inhibitors in normal clinical practice is associated with lower risk of heart failure, cardiovascular […]

Disputation: Vibeke Gagnum

Vibeke Gagnum defends her doctoral dissertation for the degree of Ph.d.: Mortality, causes of death and end-stage renal disease in type 1 diabetes. Time and place: June 13th 2017 at 13:15, Gamle Festsal, Domus Academica (Urbygningen). Her trial lecture will be held on June 13th 2017 at 10:15, Gamle Festsal, Domus Academica (Urbygningen). Read more

Disputation: Jørn Petter Hanto Lindahl

Jørn Petter Hanto Lindahl defends his doctoral dissertation for the degree of Ph.d.: Pancreas and Kidney Transplantation in Patients with Type 1 Diabetes and End-Stage Renal Disease: Long-Term Outcomes. Time and place: March 31st 2017 at 12:15, Store auditorium, Oslo universitetssykehus HF, Rikshospitalet (B), Sognsvannsveien 20. His trial lecture will be held on March 31st 2017 at 10:15, Store auditorium, […]